The latest trading day saw Teladoc (TDOC) settling at $5.91, representing a -6.04% change from its previous close.
Teladoc Health, Inc. (TDOC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Shares of Teladoc Health, Inc. (NYSE: TDOC - Get Free Report) have been given an average recommendation of "Hold" by the eighteen research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and five have given a buy recommendation
In the latest trading session, Teladoc (TDOC) closed at $7.57, marking a -5.38% move from the previous day.
Teladoc's revenue keeps sliding as its online therapy business, BetterHelp, remains under pressure. Management is "repositioning" its business, and investors may need patience.
Teladoc Health, Inc. (TDOC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock?
TDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.
Telehealth is not the new healthcare in 2025, but it has become an integrated and essential part of the healthcare landscape, transforming delivery, access, and convenience. First off, some legislation.
Teladoc Health deepens its virtual care reach by adding TytoCare's at-home exam tech to Primary360 and 24/7 Care starting in 2026.
Teladoc Health continues to see declining revenues and limited growth catalysts, with Q3 results showing a 2.2% YoY revenue decline. TDOC's recent acquisitions, including UpLift and Catapult Health, have not meaningfully offset declining user numbers or driven innovation. Despite trading at a low valuation near $7 and just 5x adjusted EBITDA, persistent growth struggles make TDOC a potential value trap.
Teladoc Health is expanding its AI-powered virtual care capabilities as the telemedicine market surges toward massive U.S. growth.